Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).
Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico
Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the motor functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of Pramipexole (PPX). Background: Parkinson's disease (PD) is characterized by both motor…Creativity related to dopaminergic treatment. A multicenter study
Objective: To study patients with Parkinson´s disease (PD) and enhanced creativity related to dopaminergic therapy. Background: Impulse control disorders (ICD) including pathological gambling, hypersexuality, and…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.